| Trapping of PARP1 and PARP2 by clinical PARP inhibitors J Murai, SYN Huang, BB Das, A Renaud, Y Zhang, JH Doroshow, J Ji, ... Cancer research 72 (21), 5588-5599, 2012 | 2200 | 2012 |
| Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib J Murai, SYN Huang, A Renaud, Y Zhang, J Ji, S Takeda, J Morris, ... Molecular cancer therapeutics 13 (2), 433-443, 2014 | 824 | 2014 |
| Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors JE Jaspers, A Kersbergen, U Boon, W Sol, L Van Deemter, SA Zander, ... Cancer discovery 3 (1), 68-81, 2013 | 542 | 2013 |
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, ... Journal of clinical oncology 27 (16), 2705-2711, 2009 | 389 | 2009 |
| Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, ... Journal of Clinical Oncology 33 (30), 3409-3415, 2015 | 333 | 2015 |
| Histone γH2AX and poly (ADP-ribose) as clinical pharmacodynamic biomarkers CE Redon, AJ Nakamura, YW Zhang, J Ji, WM Bonner, RJ Kinders, ... Clinical cancer research 16 (18), 4532-4542, 2010 | 305 | 2010 |
| Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, ... Cancer research 71 (17), 5626-5634, 2011 | 304 | 2011 |
| Rationale for poly (ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition J Murai, Y Zhang, J Morris, J Ji, S Takeda, JH Doroshow, Y Pommier Journal of Pharmacology and Experimental Therapeutics 349 (3), 408-416, 2014 | 291 | 2014 |
| Fidelity of HIV-1 reverse transcriptase copying RNA in vitro J Ji, LA Loeb Biochemistry 31 (4), 954-958, 1992 | 284 | 1992 |
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, ... Clinical cancer research 18 (6), 1726-1734, 2012 | 233 | 2012 |
| Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses JM Lee, JL Hays, CM Annunziata, AM Noonan, L Minasian, JA Zujewski, ... Journal of the National Cancer Institute 106 (6), dju089, 2014 | 226 | 2014 |
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ... Clinical cancer research 18 (8), 2344-2351, 2012 | 191 | 2012 |
| Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23 A Shatunov, N Sambuughin, J Jankovic, R Elble, HS Lee, AB Singleton, ... Brain 129 (9), 2318-2331, 2006 | 188 | 2006 |
| Advances in using PARP inhibitors to treat cancer S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, ... BMC medicine 10, 1-5, 2012 | 178 | 2012 |
| Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors A Thomas, CE Redon, L Sciuto, E Padiernos, J Ji, MJ Lee, A Yuno, S Lee, ... Journal of Clinical Oncology 36 (16), 1594-1602, 2018 | 154 | 2018 |
| Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant … S Kummar, AM Oza, GF Fleming, DM Sullivan, DR Gandara, ... Clinical cancer research 21 (7), 1574-1582, 2015 | 147 | 2015 |
| DNA banking for epidemiologic studies: a review of current practices K Steinberg, J Beck, D Nickerson, M Garcia-Closas, M Gallagher, ... Epidemiology 13 (3), 246-254, 2002 | 141 | 2002 |
| Designing phase 0 cancer clinical trials AJ Murgo, S Kummar, L Rubinstein, M Gutierrez, J Collins, R Kinders, ... Clinical cancer research 14 (12), 3675-3682, 2008 | 130 | 2008 |
| Phase 0 clinical trials: conceptions and misconceptions S Kummar, L Rubinstein, R Kinders, RE Parchment, ME Gutierrez, ... The Cancer Journal 14 (3), 133-137, 2008 | 121 | 2008 |
| Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice R Kinders, RE Parchment, J Ji, S Kummar, AJ Murgo, M Gutierrez, ... Molecular interventions 7 (6), 325, 2007 | 113 | 2007 |
Alice ChenNational Cancer Institute在 mail.nih.gov 的电子邮件经过验证
